These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 7527293)

  • 41. Dystonic reaction and relapse with clozapine discontinuation and risperidone intiation.
    Dickson R; Williams R; Dalby JT
    Can J Psychiatry; 1994 Apr; 39(3):184. PubMed ID: 7518338
    [No Abstract]   [Full Text] [Related]  

  • 42. Open trial of risperidone in 24 young children with pervasive developmental disorders.
    Masi G; Cosenza A; Mucci M; Brovedani P
    J Am Acad Child Adolesc Psychiatry; 2001 Oct; 40(10):1206-14. PubMed ID: 11589534
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The autistic-spectrum disorders.
    Rapin I
    N Engl J Med; 2002 Aug; 347(5):302-3. PubMed ID: 12151466
    [No Abstract]   [Full Text] [Related]  

  • 44. Pharmacotherapy of schizophrenia: a review.
    Sigmundson HK
    Can J Psychiatry; 1994 Nov; 39(9 Suppl 2):S70-5. PubMed ID: 7533053
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Pharmacotherapy of children and adolescents with pervasive developmental disorders.
    Hanft A; Hendren RL
    Essent Psychopharmacol; 2004; 6(1):12-24. PubMed ID: 15612651
    [No Abstract]   [Full Text] [Related]  

  • 46. Methylphenidate for pervasive developmental disorders: safety and efficacy of acute single dose test and ongoing therapy: an open-pilot study.
    Di Martino A; Melis G; Cianchetti C; Zuddas A
    J Child Adolesc Psychopharmacol; 2004; 14(2):207-18. PubMed ID: 15319018
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Iloperidone for the management of adults with schizophrenia.
    Crabtree BL; Montgomery J
    Clin Ther; 2011 Mar; 33(3):330-45. PubMed ID: 21600386
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Brief report: effects of fenfluramine on communicative, stereotypic, and inappropriate behaviors of autistic-type mentally handicapped individuals.
    Duker PC; Welles K; Seys D; Rensen H; Vis A; van den Berg G
    J Autism Dev Disord; 1991 Sep; 21(3):355-63. PubMed ID: 1938781
    [No Abstract]   [Full Text] [Related]  

  • 49. Risperidone and explosive aggressive autism.
    Horrigan JP; Barnhill LJ
    J Autism Dev Disord; 1997 Jun; 27(3):313-23. PubMed ID: 9229261
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Long-term risperidone for pervasive developmental disorder: efficacy, tolerability, and discontinuation.
    Zuddas A; Di Martino A; Muglia P; Cianchetti C
    J Child Adolesc Psychopharmacol; 2000; 10(2):79-90. PubMed ID: 10933118
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The treatment of autistic children with risperidone.
    Dodig-Curković K; Curković M; Radić J; Radić M
    Coll Antropol; 2011 Jan; 35 Suppl 1():297-301. PubMed ID: 21648351
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The pharmacotherapy of target symptoms associated with autistic disorder and other pervasive developmental disorders.
    Posey DJ; McDougle CJ
    Harv Rev Psychiatry; 2000; 8(2):45-63. PubMed ID: 10902094
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Novel neuroleptics in schizophrenia: theory and clinical relevance.
    Remington GJ
    Can J Psychiatry; 1994 Nov; 39(9 Suppl 2):S43-5. PubMed ID: 7533050
    [No Abstract]   [Full Text] [Related]  

  • 54. Risperidone for the core symptom domains of autism: results from the study by the autism network of the research units on pediatric psychopharmacology.
    McDougle CJ; Scahill L; Aman MG; McCracken JT; Tierney E; Davies M; Arnold LE; Posey DJ; Martin A; Ghuman JK; Shah B; Chuang SZ; Swiezy NB; Gonzalez NM; Hollway J; Koenig K; McGough JJ; Ritz L; Vitiello B
    Am J Psychiatry; 2005 Jun; 162(6):1142-8. PubMed ID: 15930063
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Reduction of hospital days in chronic schizophrenic patients treated with risperidone: a retrospective study.
    Addington DE; Jones B; Bloom D; Chouinard G; Remington G; Albright P
    Clin Ther; 1993; 15(5):917-26. PubMed ID: 7505716
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Neuroleptic sensitivity to risperidone in Lewy body dementia.
    McKeith IG; Ballard CG; Harrison RW
    Lancet; 1995 Sep; 346(8976):699. PubMed ID: 7544860
    [No Abstract]   [Full Text] [Related]  

  • 57. Pathophysiology and treatment of negative symptoms.
    Villeneuve A
    Can J Psychiatry; 1994 Nov; 39(9 Suppl 2):S53-8. PubMed ID: 7533052
    [TBL] [Abstract][Full Text] [Related]  

  • 58. An open clinical trial of risperidone monotherapy in young children with autistic disorder.
    Findling RL; Maxwell K; Wiznitzer M
    Psychopharmacol Bull; 1997; 33(1):155-9. PubMed ID: 9133768
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Risperidone in the treatment of disorders with a combined psychotic and depressive syndrome--a functional approach.
    Hillert A; Maier W; Wetzel H; Benkert O
    Pharmacopsychiatry; 1992 Sep; 25(5):213-7. PubMed ID: 1384075
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Double-blind comparison of risperidone and haloperidol in schizophrenic and schizoaffective psychoses.
    Cesková E; Svestka J
    Pharmacopsychiatry; 1993 Jul; 26(4):121-4. PubMed ID: 7694306
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.